Edgewise jumps ahead of “key stock-moving event”

Shares of Edgewise Therapeutics ( NASDAQ: EWTX ) added ~10% on Tuesday after Piper Sandler cited a potential catalyst related to the company’s experimental heart disease therapy, EDG-7500. EDG-7500, an oral therapy targeted at hypertrophic cardiomyopathy (HM) and other cardiac disorders, is currently undergoing a Phase 1 trial in.